Latest news with #C1
Yahoo
6 hours ago
- Business
- Yahoo
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
Reflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla., July 02, 2025--(BUSINESS WIRE)--Dyadic International, Inc. ("Dyadic") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially focused enterprise. The new name and revised visual identity reflect Dyadic's strategic emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms. The rebrand underscores Dyadic's focus on commercializing high value, non-therapeutic proteins that it believes are essential to life sciences, food, nutritional, and industrial bioprocessing applications. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics – enabling faster time to revenue, broader market reach, and long-term supply agreements. Recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, discussed below, underscore Dyadic's strategic shift toward focusing on the commercial execution and market readiness of its C1 and Dapibus™ platforms. "As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution," said Joe Hazelton, President and Chief Operating Officer of Dyadic. "The progress on our second non-animal dairy enzyme program – which recently triggered a $250,000 milestone payment – reflects the tangible outcomes of our new focus on commercialization. This rebranding reflects our top priority to deliver high-value input proteins at commercial scale." In parallel with its internal commercial focus, Dyadic continues to advance legacy collaborations with key global health partners. Dyadic recently achieved milestones in its partnership with the Gates Foundation, resulting in a second installment of $1.5 million in non-dilutive funding from a $3.0 million grant to further develop low-cost monoclonal antibodies (mAbs) for diseases such as malaria and RSV. Dyadic remains on track to commercialize its input proteins in 2025, and we believe Dyadic Applied BioSolutions is positioned to deliver sustained revenue and long-term value growth through its production platforms. About Dyadic Applied BioSolutions Dyadic Applied BioSolutions is a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications across the life sciences, food and nutrition, and industrial biotechnology sectors. These proteins are expected to serve as essential components in bioprocessing, formulation, and product development, enabling innovation without the regulatory complexity and high costs associated with therapeutic biologics. Dyadic's proprietary microbial platforms are built on the industrially proven, highly productive and GRAS-accepted fungal host Thermothelomyces heterothallica. Its lead technology, the C1 Expression System, delivers precision engineered proteins and production strains that have redefined performance, scalability, and economy for life sciences and pharmaceutical applications. Dyadic's Dapibus™ platform is expected to further expand its capabilities into food, nutrition, wellness and industrial applications, offering rapid development and large-scale production of recombinant proteins and other biological inputs. For more information, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its strategic rebranding. Forward-looking statements involve many risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, the Company's history of net losses; the Company's capital needs; market and regulatory acceptance of the Company's microbial protein production platforms and other technologies, failure to commercialize the Company's microbial protein production platforms or the Company's other technologies; competition, including from alternative technologies; the results of nonclinical studies and clinical trials; changes in global economic and financial conditions; the Company's reliance on information technology; the Company's dependence on third parties; government regulations and environmental, social and governance issues; and intellectual property risks. For a more complete description of the risks that could cause the Company's actual results to differ from the Company's current expectations, please see the section entitled "Risk Factors" in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website and at All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in the Company's expectations. View source version on Contacts Dyadic Applied BioSolutionsPing W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@
Business Wire
6 hours ago
- Business
- Business Wire
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
JUPITER, Fla.--(BUSINESS WIRE)--Dyadic International, Inc. ('Dyadic') (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially focused enterprise. The new name and revised visual identity reflect Dyadic's strategic emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms. "This rebranding reflects our top priority to deliver high-value input proteins at commercial scale." The rebrand underscores Dyadic's focus on commercializing high value, non-therapeutic proteins that it believes are essential to life sciences, food, nutritional, and industrial bioprocessing applications. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics – enabling faster time to revenue, broader market reach, and long-term supply agreements. Recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, discussed below, underscore Dyadic's strategic shift toward focusing on the commercial execution and market readiness of its C1 and Dapibus™ platforms. 'As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution,' said Joe Hazelton, President and Chief Operating Officer of Dyadic. 'The progress on our second non-animal dairy enzyme program – which recently triggered a $250,000 milestone payment – reflects the tangible outcomes of our new focus on commercialization. This rebranding reflects our top priority to deliver high-value input proteins at commercial scale.' In parallel with its internal commercial focus, Dyadic continues to advance legacy collaborations with key global health partners. Dyadic recently achieved milestones in its partnership with the Gates Foundation, resulting in a second installment of $1.5 million in non-dilutive funding from a $3.0 million grant to further develop low-cost monoclonal antibodies (mAbs) for diseases such as malaria and RSV. Dyadic remains on track to commercialize its input proteins in 2025, and we believe Dyadic Applied BioSolutions is positioned to deliver sustained revenue and long-term value growth through its production platforms. About Dyadic Applied BioSolutions Dyadic Applied BioSolutions is a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications across the life sciences, food and nutrition, and industrial biotechnology sectors. These proteins are expected to serve as essential components in bioprocessing, formulation, and product development, enabling innovation without the regulatory complexity and high costs associated with therapeutic biologics. Dyadic's proprietary microbial platforms are built on the industrially proven, highly productive and GRAS-accepted fungal host Thermothelomyces heterothallica. Its lead technology, the C1 Expression System, delivers precision engineered proteins and production strains that have redefined performance, scalability, and economy for life sciences and pharmaceutical applications. Dyadic's Dapibus™ platform is expected to further expand its capabilities into food, nutrition, wellness and industrial applications, offering rapid development and large-scale production of recombinant proteins and other biological inputs. For more information, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its strategic rebranding. Forward-looking statements involve many risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, the Company's history of net losses; the Company's capital needs; market and regulatory acceptance of the Company's microbial protein production platforms and other technologies, failure to commercialize the Company's microbial protein production platforms or the Company's other technologies; competition, including from alternative technologies; the results of nonclinical studies and clinical trials; changes in global economic and financial conditions; the Company's reliance on information technology; the Company's dependence on third parties; government regulations and environmental, social and governance issues; and intellectual property risks. For a more complete description of the risks that could cause the Company's actual results to differ from the Company's current expectations, please see the section entitled 'Risk Factors' in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC'), as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website and at All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in the Company's expectations.
India Today
7 days ago
- India Today
iPhone 17 Air said to feature C1 modem made by Apple, here is what that means for you
Apple's push to take greater control over its hardware continues. According to recent reports, the company is working on a refreshed in-house modem. The rumour has it that the upcoming iPhone 17 Air will debut the company's in-house C1 modem. Launched alongside the iPhone 16e last month, the C1 marks the Cupertino-based tech giant's first proprietary cellular modem. This move marks a significant shift in Apple's strategy to reduce its reliance on third-party suppliers, most notably Qualcomm, for key components that power wireless connectivity in its devices. So, what exactly is the C1 modem, and what difference will it make to the iPhone 17 Air's performance? Let's find out. advertisementApple's C1 modemThe C1 is Apple's first-generation baseband chip, designed to handle the iPhone's mobile network communications. Unlike processors or GPUs, baseband modems don't need to adopt an advanced manufacturing process to deliver meaningful gains. In fact, the C1 combines various process technologies, say, its core baseband logic is built on 4/5nm nodes, while the low-frequency and intermediate frequency transceivers (TRx) use 7nm technology. The power management integrated circuit (PMIC) relies on a more mature 55nm balanced approach allows Apple to optimise performance and cost without chasing the latest semiconductor processes, like 3nm, that deliver minimal benefits for modems. While newer manufacturing nodes can improve power efficiency, the baseband isn't the biggest power drain on a smartphone's wireless system, so the returns are does this mean for iPhone 17 Air users?advertisement The current C1 modem is designed to deliver solid transmission speeds and reliable network performance on existing 4G and sub-6GHz 5G networks. However, Apple is also working on a refreshed version of the C1, aimed at mass production next year. This updated modem promises better power efficiency and faster transmission rates, alongside support for mmWave 5G — the high-frequency, ultra-fast wireless standard that's been slower to roll out adding mmWave support isn't technically difficult, Apple's challenge lies in achieving consistent performance without significantly impacting battery life — an area where the refreshed C1 will reportedly bring meaningful improvements. Interestingly, the mmWave transceivers and front-end components are expected to use a 28nm process, again highlighting that for this type of hardware, newer isn't always consumers, the shift to an Apple-designed modem could offer a few benefits, including tighter integration with the rest of the iPhone's hardware, potentially more consistent real-world connectivity, and in the long term, a platform for Apple to innovate in ways that third-party solutions might not don't expect dramatic changes in your day-to-day experience just yet, the real gains will come gradually, as Apple refines its modem technology in future devices. iPhone 17 Air: What to expect advertisementThe upcoming iPhone 17 Air is rumoured to feature a silicon-carbon battery, which could help deliver better battery life than many had anticipated, despite the device's compact size. Previous leaks suggest the ultra-slim handset will pack a 2,800mAh battery — notably smaller than that of the base iPhone model — but the adoption of silicon-carbon technology may offset this with improved to be Apple's slimmest and one of its lightest smartphones to date, the iPhone 17 Air is said to weigh around 146g. This would align with recent reports pointing to a device designed to be both light and sleek. As with other recent models, the handset is expected to support Face ID for biometric a bid to keep the weight down, Apple is reportedly opting for a frame made from 7000 series aluminium alloy, rather than the titanium used in the iPhone 16 Pro and 16 Pro Max. The frame itself could weigh up to 30g, according to some sources. The heaviest components are said to be the 120Hz OLED display and the silicon-carbon battery, each reportedly tipping the scales at specifications are also rumoured to include a single 48-megapixel rear camera and a 24-megapixel front camera for selfies and video calls. Powering the device will likely be Apple's forthcoming A19 chip, paired with 8GB of RAM — similar to what was offered with the iPhone 16 Plus. The iPhone 17 Air is also expected to feature a glass back and support for wireless charging via true, these details suggest Apple is aiming to deliver a slim, lightweight handset without compromising on performance or features. However, as with all pre-launch leaks, these details should be treated with caution until the official unveiling.- Ends
Yahoo
20-06-2025
- Sport
- Yahoo
Fox fired up for canoe world titles after rough results
There's been some rough water for Jessica Fox since her Paris Olympics medal blitz, but the canoe great feels her title defence is on track 100 days out from the world championships in Penrith. Fox will defend her kayak crown on her home course, with the competition getting under way on September 29, but despite winning gold in the event in Paris, her results this year haven't been at her usual standard. Advertisement The 31-year-old, who owns six Olympic medals, including three gold, has missed the K1 final at both of the opening World Cup events in Europe. In the opening race in La Seu in Spain, Fox finished 48th in a field of 50 after incurring a 50-second penalty for missing a gate. She also missed the K1 final at the second World Cup event in Pau in France, but at both she bounced back to win gold in the C1 races. "It's funny, people are always almost shocked when you don't qualify for the final, or when you don't win, as when you've done it so many times it's just expected, but actually it's hard every time," Fox said from Prague, ahead of another World Cup later this month. Jessica Fox and her father Richard Fox celebrate with fans after a golden effort in Paris. (Dean Lewins/AAP PHOTOS) "Even the best athletes make mistakes, so it was disappointing, I was upset, I had a good cry about it, and then I just got back on the horse the next day, got back in my boat and had another crack. Advertisement "I'm fine-tuning things and I'm still in a training and building phase at the moment before the worlds, and I'm taking in as much info as I can." She said the gates hung quite low in Spain, and she was too cautious in her approach. But after taking time out to savour her Olympic success, also winning gold in the C1 while her sister Noemie won the kayak cross, she felt she was building nicely for the world championships. Fox admitted the pressure of defending her title on her home course could be on par with the Olympics. Jessica Fox knows there will be high expectations after her successes at the Paris Olympics. (Dean Lewins/AAP PHOTOS) "Paris was magical in every way and it went perfectly, and was a very successful campaign, and fantastic to perform in that way,'' she said. Advertisement "Now looking forward, obviously you're always going to have that expectation and target on your back, you're the reigning Olympic champion, reigning world champion in the kayak, and that hovers there, like a cloud, if you let it. "Everyone's hungry for that race, and just because you're world number one or just because you're the reigning champion doesn't mean it's different. "Coming into a world championship at home is going to feel very much like an Olympics in terms of the pressure and the expectation, but I think we'll be ready. "I love our home course and that's going to serve me, and I'm going to try and make it an advantage." Olympic gold medallist Jessica Fox loves the Penrith course and plans to use it as an advantage. (Dan Himbrechts/AAP PHOTOS) While she's set to compete in the next Olympics in Los Angeles, Fox is also looking beyond her paddling career and has partnered with charity organisation High Impact Athletes, with sponsors pledging an amount for each "clean" gate on the course. Advertisement "It's about looking beyond sport and going, how else can I have an impact, and how do I keep this interesting and exciting, and what's my legacy going to be?,'' she said. "Each race, each run, each gate that I take, I'm pledging my support for this charity, which provides safe, clean drinking water for people around the world, and bringing people on board with me."
Yahoo
17-06-2025
- Automotive
- Yahoo
Startup unveils 'generation-defining' vehicle that looks straight out of sci-fi movie: 'Unlike anything else in the world'
It looks like something straight out of Blade Runner, but a new two-wheel electric vehicle from Lit Motors proves that truth is often better than fiction. In a recent video showcasing the prototype, Lit Motors founder and CEO Daniel Kim called the fully enclosed EV "a Ford Model T of the 21st century." The C-1, as it's named, is a "self-balancing car that's unlike anything else in the world," Kim said. With what Kim described as a "world-class team of automotive and robotics experts," Lit Motors has built several prototypes of the C-1 over the last decade. It has a nine-year production plan in progress, with a new beta prototype set to be ready by 2026, according to New Atlas. The e-motorcycle drives up to just over 100 mph, a slower speed than the original vision of 125 mph, with a range of 170 miles. And even though early models have featured only about half the torque expected in the production version, the team is certain its invention will be a game-changer in the sustainable driving space — not as a replacement but as a supplement. "Our generation-defining product complements the adoption of EVs with a safe, high-performance, next-level commuter vehicle," said Natalia Amijo, creative director of product design. "It can easily perform daily errands and conveniently park in urban areas globally." Kim emphasized that the company was far from finished with improving and upgrading the design. "I have a couple of ideas for our next revision," he told New Atlas. "I've got some tricks up my sleeve for what the real potential of this vehicle will be." Even before this futuristic offering is available, more and more drivers around the world are opting to upgrade to EVs — for good reasons. Making the switch dramatically lowers both fuel and maintenance costs, as EVs don't require regular fluid replacements or oil changes. They also have quieter engines and produce no tailpipe pollution — which means much less in-car pollution too. And of course, opting to use electricity rather than dirty fossil fuels is an excellent way to reduce your pollutive footprint and keep toxic emissions down for a better future. If you were going to purchase an EV, which of these factors would be most important to you? Cost Battery range Power and speed The way it looks Click your choice to see results and speak your mind. For all these reasons, buyers around the world continue to be EV happy. In 2024, more than one-fifth of all new cars sold worldwide were electric, a 25% jump from the year prior, per the International Energy Agency. For EV drivers who really want to enhance their savings, charging costs drop to nearly $0 when an EV is charged using a solar panel system. If you're interested in an installation for your home, check out vetted quotes with free comparison tools at EnergySage, which offers an easy first step and can save you up to $10,000. Also, Palmetto's LightReach solar leasing program offers solar installations for no money down, providing even more Americans the opportunity to benefit from solar power. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
